Search Results

FBC Announces New Partnership with Bayer to Drive Vision Research in Canada

At Fighting Blindness Canada (FBC), our goal is to drive the development and availability of treatments and cures for blinding eye diseases. Curing blindness is a gargantuan mission, but we know it’s...

Protecting Patients by Encouraging Oversight: Can Civil Lawsuits Help?

Stem cell treatments have been advertised as miracle cures for many illnesses, including vision loss—but not all advertised “treatments” work, and some have even proven dangerous. Last year, three patients with age-related...

Everything You Need to Know About FBC’s Canada’s Patient Registry

Fill out the online form on our Patient Registry page to learn more about how you can enroll. Click here to download a printable version of this article/fact sheet: PDF/Word. The Patient...

Four Vision Research and Treatment Trends to Watch in 2018   

With the December 2017 announcement that the world’s first ocular gene therapy had received approval by the U.S. Food and Drug Administration (FDA), there’s no doubt that 2017 was a landmark year...

First gene therapy for a blinding eye disease receives FDA approval

Today we are celebrating the FDA’s pathbreaking approval of Luxturna. We have been following the development of Luxturna closely. Today’s landmark FDA approval makes Luxturna the first gene therapy approved in the...

The Value of iPSCs for Stem Cell Therapy

Stem cell therapy has emerged as one of the most promising approaches in the fight to end blindness, and Dr. Gilbert Bernier’s research has played an enormous role in pushing the field...